Bibliography
- Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4
- Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5
- Jhaveri MD, Sagar DR, Elmes SJR, et al. Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain. Mol Neurobiol 2007;36:26-35
- Devane WA, Hanus L, Breuer R, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;2581:946-49
- Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83-90
- Jonsson KO, Holt S, Fowler CJ. The endocannabinoid system: current pharmacological research and therapeutic possibilities. Basic Clin Pharmacol Toxicol 2006;98:124-34
- Hohmann AG, Suplita RL. Endocannabinoid mechanisms of pain modulation. AAPS Journal 2006;8:693-708
- DiMarzo V, De Petrocellis L. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med 2006;57:553-74
- Maejima T, Ohno-Shosaku T, Kano M. Endogenous cannabinoid as a retrograde messenger from postynaptic neurons to presynaptic terminals. Neurosci Res 2001;40:205-10
- Staton PC, Hatcher JP, Walker DJ, et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 2008;139(1):225-36
- Schneider U, Seifert J, Karst M, et al. Das endogene Cannabinoidsystem. Nervenarzt 2005;76:1062-76
- Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT-1A receptors. Neurochemical Research 2005;30(8):1037-43
- Cravatt BF, Demarest MP, Patricelli MH, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. PNAS 2001;98:9371-6
- Jhaveri MD, Richardson D, Chapman V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 2007;152:624-32
- Fowler CJ. The pharmacology of the cannabinoid system – a question of efficacy and selectivity. Mol Neurobiol 2007;36:15-25
- Fowler CJ, Holt S, Tiger G. Acidic non-steroidal antiinflammatory drugs inhibit rat brain fatty acid amide hydrolase in a ph-dependent manner. E Enzym Inhib Med Chem 2003;18:55-8
- Agarwal N, Pacher P, Tegeder I, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007;10:870-79
- Wotherspoon GA, Fox P, Mcintyre S, et al. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 2005;35:235-45
- Romero-Sandoval A, Eisenach JC. Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology 2007;106:787-94
- Hohmann AG, Suplita RL, Bolton NM, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005;435:1108-12
- Naef M, Curatolo M, Petersen-Felix S, et al. The analgesic effect of oral δ9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003;105:79-88
- Kraft B, Frickey NA, Kaufmann RM, et al. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 2008;109:101-10
- Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007;107:785-96
- Raft D, Gregg J, Ghia J, Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Clin Pharmacol Ther 1977;21:26-33
- Greenwald MK, Stitzer ML. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend 2000;59:261-75
- Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular Levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981;21:320S-326S
- Holdcroft A, Maze M, Doré C, et al. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006;104:1040-6
- Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anesth 2006;53:769-75
- Buggy DJ, Toogood L, Maric S, et al. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 2003;106:169-72
- Campbell FA, Tramèr MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review BMJ 2001;323:1-6
- Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Ther 2002;95:127-35
- Grant I, Cahn BR. Cannabis and endocannabinoid modulators: therapeutic promises and challenges. Clin Neurosci Res 2005;5:185-99
- Azad SC, Rammes G. Cannabinoids in anaesthesia and pain therapy. Curr Opin Anaesthesiol 2005;18:424-27
- Amar MB. Cannnabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 2006;105:1-25
- McCarberg BH, Barkin RL. The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview. Am J Ther 2007;14(5):475-83Sep-Oct
- Russo EB. Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management 2008;4(1):245-59
- Beaulieu P, Ware M. Reassessment of the role of cannabinoids in the management of pain. Curr Opin Anaesthesiol 2007;20:473-77
- Noyes R Jr, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975;15:139-43
- Petro DJ, Ellenberger C. Treatment of human spasticity with delta-9-tetrahydrocannabinol. J Clin Pharmacol 1981;21:413S-416S
- Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983;13:669-71
- Ungerleider JT, Andrysiak T, Fairbanks L. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987;7:39-50
- Svendson KB, Jensen TS, Back FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? BMJ 2004;329:253-61
- Holdcroft A, Smith M, Jacklin A, et al. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997;52:483-88
- Killestein J, Hoogervorst ELJ, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002;58:1404-07
- Fox P, Bain PG, Glickman S, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004;62:1105-09
- Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety, and tolerability of an oral administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004;10:417-24
- Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicenter randomised placebo-controlled trial. Lancet 2003;362:1517-26
- Lindstrom P, Lindblom U, Boreus L. Lack of effect of cannabidiol in sustained neuropathia. In: Proceeedings of the Marijuana 1987 International Conference on Cannabis; Sept 2-4; Melbourne, Australia;1987
- Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet 1995;345:579
- Pinsger M, Schimetta W, Volc D, et al. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain: a randomized controlled trial. Wien Klin Wochenschr 2006;118:327-35
- Wissel J, Haydn T, Muller J, et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol 2006;253:1337-41
- Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow-up. J Neurol Neurosurg Psychiatry 2005;76:1664-69
- Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007;68:515-21
- Tetrault JM, Crothers K, Moore BA, et al. Effects of marijuana smoking on pulmonary function and respiratory complications. Arch Intern Med 2007;167:221-28
- Guy GW, Robson P. A Phase I, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a cannabis based medicine extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in health male and female volunteers (GWPK0112). J Cannabis Ther 2003;3(4):79-120
- Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007;4(8):1770-804
- Russo EB, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006;66(2):234-46
- Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole plant cannabis extracts can improve intractable neurogenic symptoms Clin Rehab 2003;17:21-9
- Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41
- Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies. Anaesthesia 2004;59:440-52
- Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief on central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain 2004;112:299-306
- Rog DJ, Nurmikko TR, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-19
- Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006;45:50-2
- Perez-Reyes M. Pharmacodynamics of certain drugs of abuse. In: Barnett G, Chang CN, editors. Pharmacokinetics and pharmacodynamics of psychoactive drugs. Foster City, CA: Biomedical Publishers;1985: p. 287-310
- Loev B, Bender PE, Dowalo F, et al. Cannabinoids:Structure-activity studies related to 1,2-dimethylheptyl derivatives. J Med Chem 1973;16:1200-06
- Burstein SH. Inhibitory and stimulatory effects of cannabinoids on eicosanoid synthesis. NIDA Research Monograph 1987;79:158-72
- Burstein SH, Karst M, Schneider U, Zurier RB. Ajulemic acid: a novel cannabinoid produces analgesia without a ‘high’. Life Sci 2004;75:1513-22
- Ahrens J, Leuwer M, Demir R, et al. Positive allosteric modulatory effects of ajulemic acid at strychnine-sensitive glycine α1 and α1β receptors. Naunyn Schmiedebergs Arch Pharmacol 2008 (doi: 10.1007/s00210-008-0366-8)
- Dyson A, Peacock M, Chen A, et al. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain 2005;116:129-37
- Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003;290:1757-62
- Salim K, Schneider U, Burstein S, et al. Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology 2005;48:1164-71
- Sumariwalla PF, Gallily R, Tchilibon S, et al. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine coallagen-induced arthritis. Arthritis Rheum 2004;50:985-88
- Vann RE, Cook CD, Martin BR, Wiley JL. Cannabimimetic properties of ajulemic acid. J Pharmacol Exp Ther 2007;320:678-86
- Burstein SH. In humans, ajulemic acid has a more favorable side-effect profile than THC for the treatment of chronic neuropathic pain. Cannabinoids 2007;2(1):1-2
- Karst M. Comments on ‘Cannabimimetic properties of ajulemic acid'. J Pharmacol Exp Ther 2007;322:420-21
- Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol: recent advances. Chem Biodivers 2007;4(8):1678-92
- Dziadulewicz EK, Bevan SJ, Brain CT, et al. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem 2007;50:3851-56
- Day A. Neuropathic pain: emerging treatments. Br J Anaesth 2008;101:48-58
- Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008;153:315-34
- Gertsch J, Leonti M, Raduner S, et al. Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci USA 2008;105(26):9099-104
- Fox A, Bevan S. Therapeutic potential of cannabinoid agonists as analgesic agents. Expert Opin Investig Drugs 2005;14:695-703
- Hanus L, Breuer A, Tchilibon S, et al. HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. PNAS 1999;96:14228-33
- Ibrahim MM, Porreca F, Lai J, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. PNAS 2005;102:3093-98
- Anand U, Otto WR, Sanchez-Herrera D, et al. Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain 2008;138:667-80
- Hosking RD, Zajicek JP. Therapeutic potential of cannabis in pain medicine. Br J Anaesth 2008;101:59-68
- Xu H, Cheng CL, Chen M, et al. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leucoc Biol 2007;82:532-41
- Belvisi MG, Patel HJ, Freund-Michel V, et al. Inhibitory activity of the novel CB2 receptor agonist, GW833972A, on guinea-pig and human sensory nerve function in the airways. Br J Pharmacol 2008;155(4):547-57
- Idris AI, Sophocleous A, Landao-Bassonga E, et al. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology 2008;149(11):5619-26
- Calignano A, La Rana G, Giufrida A, Piomelli. Control of pain initiation by endogenous cannabinoids. Nature 1998;394:277-81
- Sulcova E, Mechoulam R, Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 1998;59:347-52
- Jayamanne A, Greenwood R, Michell VA, et al. Actions of the FAAH inhibitor URB597 in neuropathic pain and inflammatory chronic pain models. Br J Pharmacol 2006;147:281-88
- Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134(4):845-52
- Wallace VCJ, Segerdahl AR, Lambert DM, et al. The effect of the palmitoylethanolamide analogue, palmitoylallaylamide (L-29) on pain behaviour in rodent models of neuropathy. Br J Pharmacol 2007;151:1117-28
- Gutierrez T, Farthing JN, Zvonok AM, et al. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol 2007;150:153-63
- Lever IJ, Pheby TM, Rice ASC. Continous infusion of the cannabinoid WIN55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity. Br J Pharmacol 2007;151:292-302
- Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998;75:111-9
- Karsak M, Gaffal E, Date R, et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 2007;316(5830):1494-7
- Rukwied R, Watkinson A, Mcglone F, Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003;102:283-8
- Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004;74:1317-24
- Yesilyurt O, Dogrul A, Gul H, et al. Topical cannabinoid enhances topical morphine antinociception. Pain 2003;105:303-8